FocalTherics (FOCL) reported a Q2 loss late Thursday of $0.39 per diluted share, widening from a loss of $0.17 a year earlier.

Analysts polled by FactSet expected a loss of $0.22.

Revenue for the three months ended June 30 was $13.2 million, up from $9.5 million a year earlier.

Analysts expected $15.1 million.

For 2026, the company reaffirmed its revenue guidance for continuing operations of $50 million to $54 million.